by April Breyer Menon | Oct 22, 2020
Venable Fizpatrick partner Ha Kung Wong spoke with The Center for Biosimilars for an article about Amy Coney Barrett’s potential appointment to the Supreme Court and what it might mean for the Affordable Care Act (ACA) and the Biologics Price Competition and...
by April Breyer Menon | Aug 21, 2020
Venable Fizpatrick partner Ha Kung Wong spoke with Law360 for an article about Amgen v. Sanofi, a case currently pending at the Federal Circuit involving patents related to the biologic drugs Praluent and Repatha. At issue in this case is whether patents claiming a...
by April Breyer Menon | Jul 9, 2020
Venable partner Ha Kung Wong spoke with Law360 for an article about patent law Federal Circuit and Supreme Court cases to watch in 2020, including cases that will decide the fate of the Affordable Care Act and therefore the Biologics Price Competition and Innovation...
by April Breyer Menon | Jun 24, 2020
On July 1, 2020, the United States Court of Appeals for the Federal Circuit will adopt several amendments to its rules of practice, which govern procedural aspects of appeals from district court patent cases and appeals from Patent Trial and Appeal Board proceedings....
by April Breyer Menon | Jun 15, 2020
Based on an announcement last week, the longtime generics manufacturer Lannett would become among the first to file for insulin glargine product approval under the 351(k) Biologics License Application pathway. Venable’s Ha Kung Wong discusses previous and future...
by April Breyer Menon | Jun 7, 2020
Despite the United States having had a biosimilar pathway for a decade now, the industry has launched just 17 biosimilars, well behind the pace in Europe and India. Several pieces of legislation have been introduced in Congress to help boost uptake, generate savings...